The impact of a precision medicine program on molecular testing rates for advanced non-small cell lung cancer (aNSCLC): Based on community-based provider survey assessment
| Autor: | Susan M Weidner, Kashyap B. Patel, Natasha Clinton |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 38:e19179-e19179 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2020.38.15_suppl.e19179 |
| Popis: | e19179 Background: Rapid development in the Precision Medicine has provided oncologists the opportunity to offer individualized approaches to treat advanced non-small lung cancer(aNSCLC), one of the most devastating cancers, which until the past decade was thought to be invariably fatal within months. Despite superior outcomes associated with targeted therapy, most patients are not tested for all guideline-recommended molecular alterations. There is a need to educate and train health care providers (HCPs) and create standard testing patterns across the care continuum. Methods: We developed and launched a precision medicine program in January 2018 through the inception of a Precision Medicine Advisory Panel made up of community oncologists, oncology pharmacists and oncology nursing and research staff. The goal of our precision medicine program is to facilitate and drive the adoption of appropriate biomarker testing. To accomplish this, we focused on the development of testing recommendations and proactive HCP education. To evaluate the effectiveness of our program, improvements have been measured through annual audience response surveys of providers treating this patient cohort. Results: Year 1 less than 30% of survey participants were always requesting tissue-based molecular testing prior to starting first-line therapy. This increased to over 70% within an 15 month timeframe. Approximately 95% of respondents never or infrequently considered both tumor- and peripheral blood-based testing. Through the survey it was demonstrated that at least 25% are ordering both always or frequently. Timing of test results is very important within this patient population. In year 1, more than 50% of survey respondents would initiate therapy before the test results were received. The survey demonstrated significant improvement in Year 2, with more than 70% reporting never or rarely start therapy ahead of result availability. Conclusions: Although there has been demonstrated progress, areas for continued improvement exist. These include tissue allocation and payer coverage for molecular testing. Through continuing education and quality initiatives, we plan to maintain and demonstrate further improvements in testing adoption and appropriate utilization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|